The Leadership Conference on Civil and Human Rights, the nation’s oldest and largest civil rights coalitions representing more than 240 organizations, has disclosed lobbying the U.S. Senate in support of legislation that would legalize marijuana federally, remove it from the Controlled Substances Act and expunge certain past marijuana convictions.
According to a federal lobbying disclosure filed today, October 26, the organization specifically identified its support for S. 5022, the Cannabis Administration and Opportunity Act, as one of its lobbying activities. The filing names Maya Wiley, the coalition’s president and CEO, and Rahul Randhava as the two individuals who participated in lobbying on the issue.
The Leadership Conference represents more than 240 national organizations and has coordinated federal civil rights advocacy since its founding in 1950. Its involvement adds an established civil rights coalition to the organizations actively advocating for comprehensive federal marijuana reform.
The Cannabis Administration and Opportunity Act was introduced July 16 by Senator Cory Booker (D), alongside Senator Chuck Schumer (D), Senator Ron Wyden (D) and numerous other Democratic senators. The legislation would remove marijuana from federal drug schedules, establish a framework for federal regulation and taxation, and provide funding for communities disproportionately affected by marijuana prohibition.
The measure also includes provisions addressing expungement of certain federal marijuana convictions and economic opportunities for communities affected by past enforcement policies. Unlike proposals that would simply move marijuana to Schedule III, the legislation would remove it entirely from the federal Controlled Substances Act.
The filing reports $270,000 in lobbying expenses during the reporting period. That figure covers the coalition’s activities across numerous federal policy areas, including civil rights, immigration, education, housing and criminal justice. It does not indicate how much was spent specifically advocating for marijuana legalization.
The disclosure also does not identify which individual senators or congressional offices were contacted. However, it explicitly lists the U.S. Senate as the target of the lobbying activity concerning S. 5022, making the coalition’s involvement in the legislation part of the public federal lobbying record.
The bill remains before the Senate Finance Committee, where it was referred following its introduction in July. No committee vote has been recorded.










